President Donald Trump’s nominee for FDA Commissioner, Martin A. Makary, MD, sought to assure senators that if confirmed, he would support efforts to expedite reviews of new drugs indicted for rare ...

Stock analysts at BMO Capital Markets started coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Get Free Report) in a ...

Dyne Therapeutics (DYN) stock gains premarket momentum as BMO Capital Markets issus a new Outperform rating on the company. Read more here.

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report)’s share price was down 6.4% during mid-day trading on Monday after Piper Sandler lowered their price target on the stock from $53.00 to $48.00.

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

When Might Dyne Therapeutics Run Out Of Money? A company's cash runway is calculated by dividing its cash hoard by its cash burn. When Dyne Therapeutics last reported its December 2024 balance ...

The Diginex team celebrates a historic milestone at Times Square, New York, after ringing the Nasdaq Closing Bell on March 6, ...

Dyne Therapeutics, Inc. announced that it will ... and 119 decrease their positions in their most recent quarter. . (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on ...

visits the Nasdaq MarketSite in Times Square. In honor of the occasion Brian Webster, President and Chief Executive Officer, rings the Opening Bell. Sign up for our newsletter to get the latest on ...

The Nasdaq closing bell ceremony will be broadcast live starting at 3:50 p.m. Eastern Time from the Nasdaq MarketSite Tower in New York City, New York. To view the broadcast, please visit ...

Feb. 27, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing life-transforming therapeutics for people living with ...